Firma Kuros Biosciences, Autor bei News-Research

Kuros Biosciences reports results for the full year 2022

15. März 2023 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, checkmate, chf, fibrin, gold, kuros, magnetos, market, patients, posterolateral, pth, revenue, seaspine, statements, with

. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF […]

Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

21. Februar 2023 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, cells, clinical, dental, ecm, gold, graft, implants, kuros, magnetos, patients, posterolateral, project, statements, with

Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds to body of evidence for MagnetOs, using data from human and animal models Kuros […]

Kuros Biosciences Announces Changes to Executive Management Team

17. Februar 2023 Firma Kuros BiosciencesPosted in FirmeninternTagged bone, domain, fhnw, financial, graft, interim, kofax, kuros, market, mba, orthobiologics, risks, statements, steel, with

Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad interim, effective February […]

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

23. November 2022 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, clinical, ddd, fibrin, graft, kuros, market, patients, Polyether, posterolateral, pth, spine, statements, tlif, with

. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial Enrollment of additional 20 patients for […]

Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

2. November 2022 Firma Kuros BiosciencesPosted in FirmeninternTagged bone, cells, clinical, gold, graft, kuros, magnetos, new, patients, posterolateral, project, research, spinal, spine, with

Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical study compares MagnetOs Granules to local autograft in patients undergoing […]

Kuros reports 73% increase in MagnetOs sales in first nine months of 2022

26. Oktober 202226. Oktober 2022 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, chf, ecm, fibrin, flex, gold, graft, kuros, magnetos, patients, peri, posterolateral, pth, statements, with

Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned […]

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

19. Oktober 2022 Firma Kuros BiosciencesPosted in MedizintechnikTagged bone, bony, cells, ecm, extender, fibrin, flex, graft, kuros, magnetos, patients, posterolateral, pth, statements, with

. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to provide more solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a […]

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

11. Oktober 2022 Firma Kuros BiosciencesPosted in AllgemeinTagged bone, bony, ecm, extender, flex, gold, graft, kuros, magnetos, patients, peri, posterolateral, sage, statements, with

First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, […]

Kuros Biosciences Appoints Chris Fair as Chief Operating Officer

3. Oktober 2022 Firma Kuros BiosciencesPosted in FirmeninternTagged bone, company, financial, graft, implant, interim, kuros, market, medical, risks, simi, spinal, spine, statements, with

Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is […]

Kuros Biosciences announces successful CHF 6.0 million private placement

15. September 202215. September 2022 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged alpha, bone, chf, clinical, dividend, fibrin, graft, kuros, magnetos, market, par, pth, spinal, statements, with

Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 […]